OmniAb (NASDAQ:OABI) Azioni

OMNIAB INC

OmniAb

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

OmniAb Inc

CoreWeave, Inc. (Nasdaq: CRWV) ("CoreWeave") announced today that it intends, subject to market and other customary conditions, to offer $1,500 million aggregate principal amount of senior notes due 2031 (the "Notes") in a private offering. The Notes will be guaranteed on a senior unsecured basis by certain wholly-owned subsidiaries of CoreWeave.
CoreWeave intends to use the proceeds from the offering of the Notes for general corporate purposes, including, without limitation, repayment of outstanding indebtedness, and to pay fees, costs and expenses in connection with the offering of the Notes.

News

Offerings

CRWV

CoreWeave Plans $1.5B Private Debt Offering to Refinance Debt and Fund Corporate Growth

BKV Corp. Executes Agreement With Midstream Energy Company To Develop New Carbon Capture And Sequestration Project At Currently Operating Natural Gas Processing Plant In East Texas

DA Davidson analyst Peter Winter maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Buy and raises the price target from $49 to $52.

Price Target

Analyst Ratings

DA Davidson Maintains Buy on U.S. Bancorp, Raises Price Target to $52

Increasing 2025 guidance
Roper now expects full year 2025 adjusted DEPS of $19.90 - $20.05, compared to previous guidance of $19.80 - $20.05. The Company increased its full year total revenue growth outlook to ~13%, compared to a previous outlook of ~12%, and continues to expect organic revenue growth of +6 – 7%.
For the third quarter of 2025, the Company expects adjusted DEPS of $5.08 - $5.12.
Roper's guidance includes the impact of the Subsplash acquisition, which is expected to close later this month. The Company's guidance excludes the impact of unannounced future acquisitions or divestitures.

Guidance

CORRECTION: Roper Technologies Raises FY2025 Adj EPS Guidance from $19.80-$20.05 to $19.90-$20.05 vs $19.94 Est; Raises FY2025 Sales Guidance from $7.88B to $7.95B vs $7.86B Est

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Amber International Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBR#NASDAQ">AMBR</a>)</h3>
<ul class="wp-block-list">
<li>On July 7, Amber International announced it filed for a $500 mixed shelf offering. The company's stock fell around 38% over the past month and has a 52-week low of $1.55.</li>
<li>RSI Value: 27.6</li>
<li>AMBR Price Action: Shares of Amber International fell 14.3% to close at $7.28 on Friday.</li>
<li>Edge Stock Ratings: Value at 9.96.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/AMBR"><img loading="lazy" decoding="async" width="443" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071634/image-268.png" alt="" class="wp-image-993459" style="width:292px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071634/image-268.png 443w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071634/image-268-300x127.png 300w" sizes="(max-width: 443px) 100vw, 443px" /></a></figure>
<h3 class="wp-block-heading">FingerMotion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNGR#NASDAQ">FNGR</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On July 15, FingerMotion posted a first-quarter loss of 4 cents per share, versus a year-ago loss of 3 cents per share. &#8220;While topline revenue showed modest movement, with margin pressure driven by evolving business dynamics, we are encouraged by the initial revenue contribution from our Command and Communication platform, as well as the steady buildout of the DaGe and Big Data businesses,&#8221; said Martin Shen, CEO of FingerMotion. The company's stock fell around 21% over the past month and <a href="https://www.benzinga.com/quote/FNGR">has a 52-week low</a> of $1.03.</li>
<li>RSI Value: 27</li>
<li>FNGR Price Action: Shares of FingerMotion fell 1.2% to close at $1.63 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">FNGR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="922" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269.png" alt="" class="wp-image-993460" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071732/image-269-768x710.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Anterix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>)</h3>
<ul class="wp-block-list">
<li>On June 24, Anterix posted downbeat quarterly sales. The company's stock fell around 19% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/ATEX"> low of $22.50.</a></li>
<li>RSI Value: 27.51</li>
<li>ATEX Ltd Price Action: Shares of Anterix gained 0.3% to close at $22.84 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">ATEX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="897" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270.png" alt="" class="wp-image-993464" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21071832/image-270-768x719.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

AMBR

ATEX

FNGR

Top 3 Tech And Telecom Stocks That Could Blast Off In Q3

JP Morgan analyst Christopher Horvers maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Neutral and raises the price target from $56 to $65.

TSCO

JP Morgan Maintains Neutral on Tractor Supply, Raises Price Target to $65

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Outperform and raises the price target from $86 to $100.

TCBI

Keefe, Bruyette & Woods Maintains Outperform on Texas Capital Bancshares, Raises Price Target to $100

HIGHLIGHTS
<ul>
<li>US$450 million project loan facility secured from new strategic partner Appian Capital Advisory to fund the development and construction of the Cariboo Gold Project in B.C., Canada
<ul>
<li>US$100 million initial draw enables the Company to accelerate project pre-construction activities and materially de-risk the Project</li>
<li>US$350 million in subsequent draws available on a final investment decision subject to certain customary project milestones and conditions precedent</li>
</ul>
</li>
<li>Strong endorsement and cornerstone financing commitment from a leading investment fund, exclusively dedicated to long-term value in the mining space</li>
<li>Initial draw to support an infill drilling campaign, certain detailed engineering, procurement, underground development, operational readiness planning, and other early works activities</li>
<li>Enhances financial flexibility with the planned repayment of its outstanding US$25 million term loan with National Bank, as it advances toward fully funding the construction of Cariboo</li>
</ul>
&nbsp;

Osisko Development Secures $250M Credit Facility For Development And Construction Of Cariboo Gold Project In Central British Columbia

Leerink Swann analyst Mani Foroohar downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform and lowers the price target from $45 to $10.

Downgrades

SRPT

Leerink Swann Downgrades Sarepta Therapeutics to Market Perform, Lowers Price Target to $10

Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) experienced an 8% year-over-year slip in Chinese sales during June.
What Happened: The company experienced a slip in sales as rivals like Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>), Xpeng Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NASDAQ">XPEV</a>), etc. gained in sales, Bloomberg reported <a href="https://www.bloomberg.com/news/articles/2025-07-21/life-atop-china-s-car-market-is-starting-to-look-shaky-for-byd">on</a> Monday.
Analysts from investment banks like Deutsche Bank expect the company to hit 5 million wholesale units in 2025, the report suggests, while Morgan Stanley lowered its projection to 5.3 million.
BYD would need to sell over 560,000 units a month to meet its annual delivery projection for 2025 of 5.5 million units sold, which could prove difficult amid electric vehicle price war scrutiny by the Chinese Communist Party, according to the report. 
However, BYD's overseas sales are on track to reach the 800,000 unit milestone the company set out to deliver this year, with 60% of that figure already achieved by BYD, the report suggests.
Why It Matters: The news comes as BYD has adopted an aggressive pricing strategy in the Chinese market with discounted prices amid fierce competition in the sector, which has <a href="https://www.benzinga.com/news/topics/25/06/45715047/byds-aggressive-pricing-triggers-ev-rat-race-stock-tumbles-authorities-voice-concern">raised concerns within</a> the Chinese government.
Despite scrutiny, BYD released <a href="https://www.benzinga.com/markets/tech/25/07/46187880/tesla-rival-byd-launches-11000-long-range-trim-of-its-best-selling-seagull-ev-as-price-war-heats-up">a long-range version</a> of its best-selling EV, the Seagull EV, for $11,000 in the market, as well as the <a href="https://www.benzinga.com/markets/tech/25/06/45855643/tesla-rival-byd-launches-15000-seal-06-sedan-as-chinas-ev-price-war-heats-up">Seal 06 EV</a> for $15,000 in China.
Elsewhere, BYD's fellow Chinese automakers Zeekr Intelligent Technologies Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) and Neta have been accused of <a href="https://www.benzinga.com/markets/asia/25/07/46512860/tesla-rival-geelys-zeekr-neta-inflated-sales-data-in-china-through-insurance-scheme-amid-zero-mileage-used-cars-row-report">inflating sales data </a>through insurance schemes in the country, according to reports in Chinese state media.
Elsewhere, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has recorded <a href="https://www.benzinga.com/markets/tech/25/07/46409821/tesla-rebounds-in-china-with-12-3k-weekly-registrations-highest-2nd-week-ever">over 12.3k insured registrations</a> for the second week of July, which is a strong rebound for Elon Musk's EV giant after a poor start to the month in China.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46512836/elon-musks-tesla-announces-3-million-model-3-units-sold-worldwide">Elon Musk&#8217;s Tesla Announces 3 Million Model 3 Units Sold Worldwide</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

BYDDF

BYDDY

TSLA

XIACY

XPEV

Tesla Rival BYD's Domestic Sales Slip 8% In June, Analysts Slash Annual Delivery Projections Amid EV Price War Scrutiny

Fiserv's Clover Launches PracticePay To Streamline Healthcare Payments For Small And Medium-Sized Healthcare Providers

Jefferies analyst Brian Tanquilut upgrades Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) from Hold to Buy and lowers the price target from $6.25 to $6.

Upgrades

AVAH

Jefferies Upgrades Aveanna Healthcare Hldgs to Buy, Lowers Price Target to $6

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $28 to $20.

JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $20

Three Democrat-led states have decided to revoke or limit health coverage for immigrants without legal status, a move that could have significant consequences for the affected individuals and the healthcare system at large.
What Happened: The states of&nbsp;California,&nbsp;Illinois and&nbsp;Minnesota&nbsp;have recently made the decision to end or reduce health coverage for immigrants without legal status,&nbsp;<a href="https://apnews.com/article/medicaid-immigrants-california-illinois-minnesota-ice-f43d5681a6e9d45d274790c2eae716ee">reported</a>&nbsp;the Associated Press. This change will affect&nbsp;hundreds of thousands of immigrants.
The programs have proven to be much more costly than initially projected, a significant concern given the states&#8217; current and future multibillion-dollar deficits. As a result, Illinois, Minnesota, and California have opted to cut back on the programs to save money.
Adult immigrants aged 42 to 64 without legal status in Illinois have been cut off from health care, resulting in estimated savings of $404 million. In Minnesota, all adult immigrants have been removed from the state program, saving nearly $57 million. California plans to halt new adult enrollments starting in 2026, projecting savings of over $3 billion over several years.
These cuts — backed by Democratic governors who once championed expanded health coverage for immigrants — are already discouraging people from seeking care, largely out of fear of arrest or deportation.
Health care providers have raised concerns about the effects of these cuts, especially the risk that fear of arrest or deportation may prevent immigrants from seeking medical care. This avoidance of preventive services could ultimately result in higher long-term costs, as more immigrants may require treatment at safety-net hospitals.
See Also: <a href="https://benzinga.com/crypto/cryptocurrency/25/07/46495773/shiba-inu-rallies-10-in-1-week-can-it-go-higher" target="_blank" rel="noreferrer noopener">Shiba Inu Rallies 10% In 1 Week: Can It Go Higher?</a>
Why It Matters: The decision to cut health coverage for immigrants without legal status comes&nbsp;at a time when the&nbsp;Trump administration has been taking steps to tighten immigration policies and enforcement.
Earlier this month, the Trump administration&nbsp;<a href="https://www.benzinga.com/news/politics/25/07/46363638/trump-ends-head-start-program-for-illegal-aliens-moves-to-cut-clinton-era-postsecondary-aid-and-other-federal-benefits">announced</a>&nbsp;that undocumented immigrants would no longer be eligible for various federal programs, including the Head Start program and several other federal benefits and programs. This decision, combined with the recent cuts in health coverage, could have a significant impact on the well-being of immigrants without legal status.
Moreover, the Trump administration&#8217;s decision to&nbsp;share 79 million Medicaid recipients&#8217; private <a href="https://www.benzinga.com/news/legal/25/07/46247689/palantir-reportedly-assisting-trump-administrations-doge-to-compile-americans-personal-data">health data</a> with Immigration and Customs Enforcement (ICE)&nbsp;has sparked legal challenges from several states, including California. The recent cuts in health coverage for immigrants without legal status may further exacerbate the already contentious relationship between the federal government and these states.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46381096/trump-administration-ordered-by-judge-to-stop-immigration-arrests-without-probable-cause-in-southern-california-report">Trump Administration Ordered By Judge To Stop Immigration Arrests Without Probable Cause In Southern California: Report</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Medicaid Cuts In 3 Democrat-Led States Strip Health Coverage From Undocumented Immigrants Amid Budget Crunch

Rogers Communications Upsizes Cash Tender Offers To $1.4B To Purchase Eight Series Of US Dollar Debt Securities

<ul>
<li>NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populations</li>
<li>Reflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19</li>
<li>New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a significant impact on cancer patients, including serious delays or even cessation of cancer treatment and prolonged complications</li>
</ul>

Biotech

Health Care

General

IVVD

Invivyd Says Updated National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology For Cancer-related Infections Now Recommend The Use Of Available Monoclonal Antibodies For Pre-exposure Prophylaxis Of Covid-19

VMAR

Octillion Power Systems And Vision Marine Technologies Expand Supplier Agreement; Octillion To Manufacture Vision-Branded Battery Packs For E-Motion 180# Electric Outboard System For US Market Distribution

CRGO

Freightos Expands South Asia Reach As SriLankan Cargo Integration Unlocks Digital Access To Colombo And Indian Subcontinent Markets

<ul>
<li>NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populations</li>
<li>Reflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19</li>
<li>New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a significant impact on cancer patients, including serious delays or even cessation of cancer treatment and prolonged complications &nbsp;</li>
</ul>
WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced the June 20, 2025 updated National Comprehensive Cancer Network&#xAE; (NCCN&#xAE;) Clinical Practice Guidelines in Oncology (NCCN Guidelines&#xAE;) for the Prevention and Treatment of Cancer-Related Infections now recommend the use of available monoclonal antibodies for pre-exposure prophylaxis of COVID-19. The NCCN Guidelines advise clinicians to refer to guidance from Infectious Diseases Society of America (IDSA), Centers for Disease Control and Prevention (CDC), or U.S. Food and Drug Administration for available monoclonal antibody options. This recommendation reflects the growing alignment among key organizations - including IDSA and CDC - reinforcing the critical role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19.
New research titled <a href="https://www.globenewswire.com/Tracker?data=h65lcNho57CRsdPWCAseEoSTMEOKZuhYODPFZLo9vnpS23gmi7nBPPJZCyBj9aVo17Urkf-i9GZDmVEj5rnjfb1bYRiBa46rX49zgiCDP2dTK5iaeTPfe82RtmswJ6inz09g9TXvzpYllfyAHnGOg5aF-pC9w60FUkOfKiEQE9HKelyZJfBo2Qh8JQtzXXe1Is4oET1t524aOkC-_wOw4LAlVeKgD7XLDNF2ItF12YeroKrTzW1fujxPriJQ5ZpF">Risk Factors for COVID-19–Related Hospitalization and Death in Patients With Cancer</a> published online on July 17, 2025 in JAMA Oncology reflects why prevention of SARS-CoV-2 is important for people with cancer. The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) provides critical insights into the long-term impact of SARS-CoV-2 infection in these individuals.
Over a two-year period, the NCCAPS study followed 1,572 eligible adult patients with cancer who also had COVID-19. The data revealed high risk of severe disease as evidenced by the rate of hospitalization, treatment delays, and mortality within 90 days among patients undergoing chemotherapy or those with hematologic malignancies, consistent with previous studies. Notably, of the 290 patients that were initially hospitalized for COVID-19, 31 patients had a second admission for sequelae of COVID-19 within 30 days of their initial admission. Over 50% of all cancer treatment disruptions in the cohort were directly attributed to COVID-19, especially during the early phase of infection. These disruptions raised concerns about continuity of care and long-term impacts on patient outcomes. These data highlight the importance of continued surveillance and prevention strategies in populations at highest risk for COVID-19 complications.

Invivyd Says Updated NCCN Guidelines For Prevention And Treatment Of Cancer-Related Infections Now Recommend Use Of Available Monoclonal Antibodies For Pre-Exposure Prophylaxis Of COVID-19

AstraZeneca's TAGRISSO Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Overall Survival For Patients With 1st-Line Locally Advanced Or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer

Press Releases

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

OmniAb to Report First Quarter 2025 Financial Results on May 8

OmniAb Announces Two New Appointments to its Board of Directors

OmniAb to Participate in Five Upcoming Investor Conferences

IPOs

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Comments

OmniAb

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO